Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann E Clarke

Showing results (1-10 of 224) with videos related to

Pageof 23
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Systemic lupus erythematosus: clinical manifestations, treatment and economicsPantelis Panopalis, Ann E Clarke
Clinical & Developmental Immunology|December 13, 2006
Quality of life in systemic lupus erythematosusPantelis Panopalis, Ann E Clarke
Paediatrics & Child Health|January 2, 2013
Food-induced anaphylaxis: Clinical highlights and knowledge gapsMoshe Ben-Shoshan, Ann E Clarke
Expert Review of Clinical Immunology|June 2, 2020
Systemic lupus erythematosus and risk of infectionMegan R W Barber, Ann E Clarke
Archives of Internal Medicine|February 27, 2008
Hematologic malignant neoplasms after drug exposure in rheumatoid arthritisSasha Bernatsky, Ann E Clarke, Samy Suissa
Best Practice & Research. Clinical Rheumatology|December 11, 2012
The economic burden of systemic lupus erythematosusPantelis Panopalis, Ann E Clarke, Edward Yelin
Current Opinion in Rheumatology|May 19, 2017
Socioeconomic consequences of systemic lupus erythematosusMegan R W Barber, Ann E Clarke
Current Rheumatology Reports|November 24, 2005
Revisiting the issue of malignancy risk in systemic lupus erythematosusSasha Bernatsky, Rosalind Ramsey-Goldman, Ann E Clarke
Best Practice & Research. Clinical Rheumatology|July 14, 2009
Malignancy in systemic lupus erythematosus: what have we learned?Sasha Bernatsky, Rosalind Ramsey-Goldman, Ann E Clarke
Rheumatology (Oxford, England)|September 29, 2017
Comment on: Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosusSasha Bernatsky, Ann E Clarke, Rosalind Ramsey-Goldman
Pageof 23

Showing results (1-10 of 224) with videos related to

Sort By:
Pageof 23
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Systemic lupus erythematosus: clinical manifestations, treatment and economicsPantelis Panopalis, Ann E Clarke
Clinical & Developmental Immunology|December 13, 2006
Quality of life in systemic lupus erythematosusPantelis Panopalis, Ann E Clarke
Paediatrics & Child Health|January 2, 2013
Food-induced anaphylaxis: Clinical highlights and knowledge gapsMoshe Ben-Shoshan, Ann E Clarke
Expert Review of Clinical Immunology|June 2, 2020
Systemic lupus erythematosus and risk of infectionMegan R W Barber, Ann E Clarke
Archives of Internal Medicine|February 27, 2008
Hematologic malignant neoplasms after drug exposure in rheumatoid arthritisSasha Bernatsky, Ann E Clarke, Samy Suissa
Best Practice & Research. Clinical Rheumatology|December 11, 2012
The economic burden of systemic lupus erythematosusPantelis Panopalis, Ann E Clarke, Edward Yelin
Current Opinion in Rheumatology|May 19, 2017
Socioeconomic consequences of systemic lupus erythematosusMegan R W Barber, Ann E Clarke
Current Rheumatology Reports|November 24, 2005
Revisiting the issue of malignancy risk in systemic lupus erythematosusSasha Bernatsky, Rosalind Ramsey-Goldman, Ann E Clarke
Best Practice & Research. Clinical Rheumatology|July 14, 2009
Malignancy in systemic lupus erythematosus: what have we learned?Sasha Bernatsky, Rosalind Ramsey-Goldman, Ann E Clarke
Rheumatology (Oxford, England)|September 29, 2017
Comment on: Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosusSasha Bernatsky, Ann E Clarke, Rosalind Ramsey-Goldman
Pageof 23